JP2019506392A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506392A5 JP2019506392A5 JP2018537867A JP2018537867A JP2019506392A5 JP 2019506392 A5 JP2019506392 A5 JP 2019506392A5 JP 2018537867 A JP2018537867 A JP 2018537867A JP 2018537867 A JP2018537867 A JP 2018537867A JP 2019506392 A5 JP2019506392 A5 JP 2019506392A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- subject
- compound
- formula
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 7
- 229960005277 gemcitabine Drugs 0.000 description 7
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DPHUWDIXHNQOSY-UHFFFAOYSA-N CC(c1cc(C(c2ccccc2C2=O)=O)c2[o]1)=O Chemical compound CC(c1cc(C(c2ccccc2C2=O)=O)c2[o]1)=O DPHUWDIXHNQOSY-UHFFFAOYSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281004P | 2016-01-20 | 2016-01-20 | |
| US62/281,004 | 2016-01-20 | ||
| PCT/US2017/014163 WO2017132049A1 (en) | 2016-01-20 | 2017-01-19 | Methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019506392A JP2019506392A (ja) | 2019-03-07 |
| JP2019506392A5 true JP2019506392A5 (enExample) | 2020-02-27 |
Family
ID=58737850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018537867A Pending JP2019506392A (ja) | 2016-01-20 | 2017-01-19 | がんを処置するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20190076392A1 (enExample) |
| EP (1) | EP3405189A1 (enExample) |
| JP (1) | JP2019506392A (enExample) |
| CN (1) | CN109069469A (enExample) |
| CA (1) | CA3011800A1 (enExample) |
| TW (1) | TW201731500A (enExample) |
| WO (1) | WO2017132049A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3067054B1 (en) | 2007-09-10 | 2020-12-30 | Boston Biomedical, Inc. | Novel compositions and methods for cancer treatment |
| MX2015014181A (es) | 2013-04-09 | 2016-05-24 | Boston Biomedical Inc | 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer. |
| EA201792287A1 (ru) * | 2015-04-17 | 2018-03-30 | Бостон Биомедикал, Инк. | Способы лечения рака |
| JP7106563B2 (ja) | 2016-11-29 | 2022-07-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | ナフトフラン誘導体、その調製、および使用方法 |
| US10646464B2 (en) | 2017-05-17 | 2020-05-12 | Boston Biomedical, Inc. | Methods for treating cancer |
| AU2019340402B2 (en) | 2018-08-17 | 2025-04-03 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
| BR112021006898A2 (pt) * | 2018-10-12 | 2021-07-20 | 1Globe Biomedical Co., Ltd. | nova solução de combinação para tratar câncer refratário à quimioterapia |
| WO2025040685A1 (en) * | 2023-08-21 | 2025-02-27 | Abliva Ab | Quinones for use in the treatment of red blood cell enzymopathies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3067054B1 (en) | 2007-09-10 | 2020-12-30 | Boston Biomedical, Inc. | Novel compositions and methods for cancer treatment |
| BR112012023661A2 (pt) | 2010-03-19 | 2020-11-24 | Boston Biomedical, Inc. | novos compostos e novas composições direcionadas a células-tronco cancerosas |
| AU2011227023B2 (en) | 2010-03-19 | 2015-05-28 | Boston Biomedical, Inc. | Novel methods for targeting cancer stem cells |
| WO2012119265A1 (en) | 2011-03-04 | 2012-09-13 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES |
| US8977803B2 (en) | 2011-11-21 | 2015-03-10 | Western Digital Technologies, Inc. | Disk drive data caching using a multi-tiered memory |
| WO2013166618A1 (en) * | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
| MX2015014181A (es) * | 2013-04-09 | 2016-05-24 | Boston Biomedical Inc | 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer. |
| EA201792287A1 (ru) * | 2015-04-17 | 2018-03-30 | Бостон Биомедикал, Инк. | Способы лечения рака |
| JP2018521979A (ja) * | 2015-06-03 | 2018-08-09 | ボストン バイオメディカル， インコーポレイテッド | 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物 |
-
2017
- 2017-01-19 US US16/070,748 patent/US20190076392A1/en not_active Abandoned
- 2017-01-19 EP EP17724464.7A patent/EP3405189A1/en not_active Withdrawn
- 2017-01-19 JP JP2018537867A patent/JP2019506392A/ja active Pending
- 2017-01-19 CN CN201780012242.4A patent/CN109069469A/zh active Pending
- 2017-01-19 WO PCT/US2017/014163 patent/WO2017132049A1/en not_active Ceased
- 2017-01-19 CA CA3011800A patent/CA3011800A1/en not_active Abandoned
- 2017-01-20 TW TW106102144A patent/TW201731500A/zh unknown
-
2019
- 2019-03-25 US US16/363,626 patent/US20190224157A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506392A5 (enExample) | ||
| JP2018511643A5 (enExample) | ||
| JP2015533176A5 (enExample) | ||
| JP2022124458A5 (enExample) | ||
| EP2435041B1 (en) | Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent | |
| JP2020514311A5 (enExample) | ||
| JP2016533366A5 (enExample) | ||
| JP2018508593A5 (enExample) | ||
| JP2018526376A5 (enExample) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2014510729A5 (enExample) | ||
| IL300151A (en) | Combinations for the treatment of cancer | |
| JP2018525358A5 (enExample) | ||
| TW201613589A (en) | Combination methods for treating cancers | |
| JP2017505321A5 (enExample) | ||
| EA200900912A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
| CA2922684A1 (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases | |
| JP2019510785A5 (enExample) | ||
| JP2017527582A5 (enExample) | ||
| JP2017533220A5 (enExample) | ||
| TNSN07294A1 (en) | Treatment of metastasized tumors | |
| JP2020520923A5 (enExample) | ||
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| JP2016531885A5 (enExample) | ||
| RU2008148597A (ru) | Фармацевтические комбинации |